Table 2.
Sensitivity and specificity of pan-TRK IHC as a screening tool for NTRK fusions with molecular assay as a reference.
| Pan-TRK IHC | Molecular Assay | |||
|---|---|---|---|---|
| Only positive IHC | Negative | Positive | Total | |
| Negative | 207 | 6 | 213 | NPV (95% CI): 97.2% (94.5–98.6%) |
| Positive | 41 | 20 | 61 | PPV (95% CI): 32.8% (25.6–40.9%) |
| Total | 248 | 26 | 274 | |
| Specificity (95% CI): 83.5% (78.3–87.9%) |
Sensitivity (95% CI): 77.0% (56.4–91.0%) |
|||
| Including inconclusive IHC | Negative | Positive | Total | |
| Negative | 207 | 6 | 213 | NPV (95% CI): 97.2% (94.4–98.6%) |
| Positive/inconclusive | 91 | 23 | 114 | PPV (95% CI): 20.2% (16.4–24.6%) |
| Total | 298 | 29 | 327 | |
| Specificity (95% CI): 69.5% (63.9–74.6%) |
Sensitivity (95% CI): 79.3% (60.3–92.0%) |
|||
Abbreviations: CI, confidence interval; IHC, immunohistochemistry; NPV, negative predictive value; PPV, positive predictive value.